AI in Market Access: The Real Opportunity Is Better Payer Alignment
AI in market access can help biopharma teams apply payer intelligence earlier and more consistently across evidence, pricing, launch, and access strategy.
Access Is a Design Decision: Why Commercial Performance Is Now Determined by Access, Not Approval
Access is now shaping commercial performance. Learn how policy, payer dynamics, and evidence are redefining access strategy and what it requires from organizations today.
Patient Support Services Modeling, Made Actionable
A data-driven approach to patient support services modeling that helps manufacturers forecast demand, evaluate program design, and manage affordability, access, and cost with confidence.
Where Ecosystem Mapping Becomes Strategy
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.
When Lower Prices Don’t Mean Lower Costs: How Part D Benefit Changes Are Shifting Out-of-Pocket Spending in 2026 Under the Inflation Reduction Act
The 2026 Medicare Part D redesign lowers some drug prices but shifts cost sharing. Coinsurance and higher deductibles may increase out-of-pocket costs for many beneficiaries.
Designing for Coverage, Not Just Approval
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
Market Access as a Driver of Biotech Value in 2026
Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
Barriers to CAR-T Access in Medicare
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
PBM Reform in the Commercial Insurance Market: Understanding the Federal Budgetary Impact
Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
Case Study: Educating on Combination Product Access
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.